Meeting
2021 Gastrointestinal Cancers Symposium
The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.
Authors
Shuichi Hironaka
Division of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu, Japan
Shuichi Hironaka , Ryo Sadachi , Tadayoshi Hashimoto , Nozomu Machida , Satoru Iwasa , Yasuhide Yamada , Mitsuru Sasako , Narikazu Boku , Takaki Yoshikawa , Masanori Terashima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
000007652
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 197)
DOI
10.1200/JCO.2021.39.3_suppl.197
Abstract #
197
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.
First Author: Feng Wang
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: A multicenter retrospective study.
First Author: Sadayuki Kawai
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.
First Author: Vikas S. Ostwal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz